The UK and EU have agreed a sweeping reset of post-Brexit relations, with measures that could change the environment for drug discovery and cross-border scientific collaboration.

shutterstock_2758584123

The UK and European Union (EU) have agreed a new package of measures to reset their post-Brexit relationship, with potential implications for the life sciences sector, including research collaboration, workforce mobility and supply chain resilience.

Announced at the UK-EU Summit in Brussels on 20 November 2026, the agreements cover food and drink trade, a youth experience scheme and the linking of UK and EU emissions trading systems. Both sides have also committed to strengthening cooperation on health security, science and technology.

Reducing barriers to trade and industry

One of the central agreements establishes a common Sanitary and Phytosanitary (SPS) area, which will remove most routine certificates and controls required for movements of animals, animal products, plants and plant products between Great Britain and the EU.

The agreement is expected to come into effect from 1 March 2028 which the Government estimates could add £5.1 billion annually to the UK economy by reducing administrative costs and easing cross-border trade.

Although primarily focused on agriculture and food production, closer alignment could also contribute to a more predictable trading environment for businesses operating across UK and European markets.

Separately, linking the UK and EU Emissions Trading Systems from 2028 is intended to reduce carbon-related trade barriers. The agreement will allow mutual recognition of emissions allowances and exemptions from respective Carbon Border Adjustment Mechanisms, subject to the relevant legal procedures.

The Government estimates this arrangement could contribute a further £3.8 billion annually to the UK economy.

Opportunities for the life sciences workforce

The agreement also establishes a Youth Experience Scheme, allowing up to 100,000 young people from each side to live in the other territory for up to three years.

The scheme will cover activities including employment, education, volunteering and travel, with the aim of implementing it no later than 2028 and making opportunities available by January 2030.

For drug discovery, improved mobility could support the exchange of early-career researchers and technical specialists between UK and European institutions. Greater opportunities to study and work across borders could also help strengthen international research networks and access to scientific expertise.

The UK will also participate in the Erasmus+ programme from 2027, providing further opportunities for education, training and professional development.

What does this mean for drug discovery?

Beyond the headline trade agreements, the joint statement outlines commitments to strengthen cooperation in science, research, technology and innovation.

Both sides intend to establish an EU-UK Digital Partnership in early 2027, potentially covering artificial intelligence, quantum technologies and other critical technologies. The statement identifies scientific research and innovation as important to economic growth and technological development, while retaining regulatory autonomy.

There are also specific commitments relating to health security, as the UK and EU have said they will work towards signing a memorandum of understanding covering health security. This includes medical countermeasures and establishing a dedicated committee under the Trade and Cooperation Agreement.

For the drug discovery community, this could provide opportunities to strengthen dialogue around preparedness, medical countermeasures and shared health threats. However, the agreement does not introduce new medicines approval arrangements or directly change pharmaceutical regulatory requirements.

The package therefore represents a broader commitment to rebuilding UK-EU cooperation rather than a direct overhaul of the drug discovery landscape. How far these commitments translate into practical research partnerships, improved access to expertise and stronger innovation networks will depend on their implementation over the coming years.